Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for OptimizeRx's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPRX vs CCLD, HCAT, DH: Total Payout Ratio Comparison
For the Health Information Services subindustry, OptimizeRx's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptimizeRx Total Payout Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where OptimizeRx's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptimizeRx (OPRX) has a Total Payout Ratio of 0.00 as of Aug. 08, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on OptimizeRx and its competitors.
Is OptimizeRx's Total Payout Ratio too high?
OptimizeRx's current Total Payout Ratio is 0.00. Overall, OptimizeRx has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does OptimizeRx's Total Payout Ratio compare to CCLD and HCAT?
OptimizeRx's Total Payout Ratio of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Healthcare Providers & Services company?
A good Total Payout Ratio depends on the Healthcare Providers & Services industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on OptimizeRx and its competitors. OptimizeRx's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptimizeRx stock overvalued right now?
Based on GuruFocus' analysis, OptimizeRx (OPRX) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.82, compared to a current price of $7.08 — trading 44.8% below its estimated fair value. The current Total Payout Ratio is 0.00. OptimizeRx's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For OptimizeRx (OPRX), the current Total Payout Ratio is 0.00 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OptimizeRx (OPRX) Overvalued in 2026?
Based on GuruFocus' analysis, OptimizeRx stock appears to be undervalued.
The current stock price of $7.08 is trading 44.8% below its estimated GF Value™ of $12.82.
GuruFocus considers OptimizeRx to be Significantly Undervalued.
Key valuation signals for OPRX:
Total Payout Ratio: 0.00
GF Value™: $12.82 vs. price of $7.08 (44.8% below fair value)
No single metric tells the full story. See the OPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
57GF Score
Get the complete analysis for OPRX
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPRX has been successfully added to your 
